← Back to Search

Platinum-based Chemotherapy

Chemotherapy +/− Ramucirumab for Thymic Cancer

Phase 2
Waitlist Available
Led By Anne S Tsao
Research Sponsored by SWOG Cancer Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have unresectable thymic carcinoma, that is either locally advanced, recurrent, or metastatic
Patients must have a Zubrod performance status of 0 to 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial tests how well carboplatin and paclitaxel work with or without ramucirumab to treat patients with thymic cancer that has spread or returned.

Who is the study for?
This trial is for adults with advanced, recurrent, or metastatic thymic cancer that can't be surgically removed. They should not have had previous systemic anti-cancer therapy for this condition and must have measurable disease. Participants need proper liver and kidney function, no significant blood clots or bleeding in recent months, controlled blood pressure, and cannot be pregnant or breastfeeding.Check my eligibility
What is being tested?
The study compares the effectiveness of chemotherapy drugs carboplatin and paclitaxel alone versus combined with ramucirumab (a monoclonal antibody) in treating thymic cancer. The goal is to see if adding ramucirumab improves treatment outcomes compared to just chemotherapy.See study design
What are the potential side effects?
Possible side effects include allergic reactions to the drugs, increased risk of infection due to lowered white blood cell counts, nausea, fatigue from chemotherapy agents like carboplatin and paclitaxel; ramucirumab may cause high blood pressure, bleeding problems including gastrointestinal bleeds or wound healing complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My thymic carcinoma cannot be removed by surgery and has spread.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
I cannot have surgery to remove my cancer.
Select...
I have not received any systemic anti-cancer treatments for my advanced thymic carcinoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival
Secondary outcome measures
Disease control rate (complete response, partial response, confirmed or unconfirmed, stable disease)
Incidence of adverse events
Overall survival
+1 more

Side effects data

From 2016 Phase 3 trial • 1253 Patients • NCT01168973
46%
Fatigue
36%
Neutropenia
32%
Diarrhoea
30%
Decreased appetite
27%
Nausea
26%
Alopecia
24%
Dyspnoea
23%
Stomatitis
22%
Cough
22%
Anaemia
19%
Epistaxis
18%
Neutrophil count decreased
17%
Oedema peripheral
17%
Constipation
16%
Mucosal inflammation
16%
Pyrexia
14%
Lacrimation increased
14%
Vomiting
14%
Febrile neutropenia
13%
Myalgia
13%
Leukopenia
12%
Back pain
12%
Peripheral sensory neuropathy
11%
Arthralgia
11%
Dysgeusia
11%
Hypertension
11%
Headache
11%
Insomnia
11%
Asthenia
11%
Weight decreased
9%
Abdominal pain
9%
White blood cell count decreased
8%
Oropharyngeal pain
8%
Pain in extremity
8%
Thrombocytopenia
7%
Rash
7%
Dizziness
7%
Nail discolouration
6%
Productive cough
6%
Dyspepsia
6%
Pain
6%
Dysphonia
6%
Dehydration
6%
Paraesthesia
6%
Haemoptysis
6%
Hyperglycaemia
6%
Pneumonia
6%
Platelet count decreased
5%
Bone pain
1%
Hyponatraemia
1%
Lobar pneumonia
1%
Metastatic pain
1%
Chronic obstructive pulmonary disease
1%
Pleural effusion
1%
Pneumothorax
1%
Pulmonary embolism
1%
Pulmonary haemorrhage
1%
Syncope
1%
Confusional state
1%
Death
1%
Atrial fibrillation
1%
General physical health deterioration
1%
Renal failure acute
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ramucirumab and Docetaxel
Placebo and Docetaxel

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A (ramucirumab, carboplatin, paclitaxel)Experimental Treatment3 Interventions
Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
Group II: Arm B (carboplatin, paclitaxel)Active Control2 Interventions
Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6670
Paclitaxel
2011
Completed Phase 4
~5380
Ramucirumab
2017
Completed Phase 3
~5050

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Thymic Carcinoma include chemotherapy agents such as carboplatin and paclitaxel, and monoclonal antibodies like ramucirumab. Chemotherapy drugs work by killing tumor cells, stopping them from dividing, or preventing them from spreading. Ramucirumab, a monoclonal antibody, interferes with the ability of tumor cells to grow and spread by targeting specific proteins involved in angiogenesis (formation of new blood vessels that supply the tumor). This combination is significant for Thymic Carcinoma patients as it offers a multi-faceted approach to inhibit tumor growth and dissemination, potentially improving treatment outcomes for those with advanced or inoperable disease.
Angiogenesis inhibitors in early development for gastric cancer.The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.

Find a Location

Who is running the clinical trial?

SWOG Cancer Research NetworkLead Sponsor
394 Previous Clinical Trials
264,554 Total Patients Enrolled
Southwest Oncology GroupLead Sponsor
388 Previous Clinical Trials
261,195 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,734 Previous Clinical Trials
40,967,538 Total Patients Enrolled
10 Trials studying Thymic Carcinoma
999 Patients Enrolled for Thymic Carcinoma

Media Library

Carboplatin (Platinum-based Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT03694002 — Phase 2
Thymic Carcinoma Research Study Groups: Arm A (ramucirumab, carboplatin, paclitaxel), Arm B (carboplatin, paclitaxel)
Thymic Carcinoma Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT03694002 — Phase 2
Carboplatin (Platinum-based Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03694002 — Phase 2
Thymic Carcinoma Patient Testimony for trial: Trial Name: NCT03694002 — Phase 2
~11 spots leftby Jun 2025